The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: A population-based cohort study-Reference-Cited by-同舟云学术

The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: A population-based cohort study

Published:2022-03 Issue: Volume:128 Page:154893
ISSN:0026-0495
Container-title:Metabolism
language:en
Short-container-title:Metabolism

Author:

Kouvari Matina,Chrysohoou Christina,Skoumas John,Pitsavos Christos,Panagiotakos Demosthenes B.,Mantzoros Christos S.

Funder

Hellenic Atherosclerosis Society

Hellenic Society of Cardiology

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference33 articles.

1. Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120,813 adults from 16 cohort studies from the USA and Europe;Kivimäki;Lancet Public Health,2017

2. Metabolic health and weight: understanding metabolically unhealthy normal weight or metabolically healthy obese patients;Mathew;Metabolism,2016

3. Metabolically healthy obesity: criteria, epidemiology, controversies, and consequences;Tsatsoulis;Curr Obes Rep,2020

4. Metabolically healthy obesity and cardiovascular events: a systematic review and meta-analysis;Eckel;Eur J Prev Cardiol,2016

5. Combined effect of obesity and cardio-metabolic abnormality on the risk of cardiovascular disease: a meta-analysis of prospective cohort studies;Fan;Int J Cardiol,2013

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?;Metabolism;2024-08

2. Preoperative nonalcoholic steatohepatitis and resolution of metabolic comorbidities after bariatric surgery;Surgery for Obesity and Related Diseases;2024-08

3. Severe obesity is associated with worse outcomes than lean metabolic dysfunction–associated steatotic liver disease;Hepatology Communications;2024-06-27

4. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges;Metabolism;2024-05

5. Adipocentric origin of the common cardiometabolic complications of obesity in the young up to the very old: pathophysiology and new therapeutic opportunities;Frontiers in Medicine;2024-04-08